Literature DB >> 20348878

Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas.

Adam C Seegmiller1, Rolando Garcia, Rong Huang, Atousa Maleki, Nitin J Karandikar, Weina Chen.   

Abstract

Rearrangement of MYC with immunoglobulin genes is a hallmark of Burkitt lymphoma. However, this rearrangement is not entirely specific and is often accompanied by varying numbers of additional cytogenetic abnormalities. This study aimed to assess the impact of karyotypic complexity, in correlation with comprehensive immunophenotypic analyses on the diagnosis and clinical outcomes of 34 cases of MYC-IG rearranged lymphomas that included Burkitt lymphoma (twenty-two cases), diffuse large B-cell lymphoma (three cases), unclassifiable B-cell lymphoma with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (six cases), and plasmablastic lymphoma (three cases). Additional cytogenetic abnormalities were observed in 26 of 34 cases (76%), including four cases (12%) that harbored dual translocations involving BCL-2 or BCl-6. Burkitt lymphoma cases had a significantly lower number of additional abnormalities (mean of 1.7), compared with unclassified B-cell lymphoma (3.3), diffuse large B-cell lymphoma (21.7), and plasmablastic lymphoma (6.7). Cases with simple karyotype (< or =2 additional abnormalities) were more likely to have a diagnosis of Burkitt lymphoma (89 versus 33% in patients with >2 additional abnormalities, P<0.01) and express bcl-6 (95 versus 47%, P<0.01). In addition, Burkitt lymphoma, bcl-6 expression, and simple karyotype were individual predictors of better overall survival. However, in multivariate analyses, only bcl-6 expression remained an independent predictor, although survival could be further stratified by karyotypic complexity in bcl-6(+) patients. We conclude that simple karyotype and bcl-6 expression suggest a diagnosis of Burkitt lymphoma and may portend better overall survival. These results may be very useful in the diagnosis and stratification of MYC-IG rearranged high-grade B-cell lymphomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20348878     DOI: 10.1038/modpathol.2010.76

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  15 in total

Review 1.  Genomics of aggressive B-cell lymphoma.

Authors:  Allison Rosenthal; Lisa Rimsza
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Definition of MYC genetic heteroclonality in diffuse large B-cell lymphoma with 8q24 rearrangement and its impact on protein expression.

Authors:  Alexandra Valera; Samantha Epistolio; Lluis Colomo; Alice Riva; Olga Balagué; Ivan Dlouhy; Alexandar Tzankov; Marco Bühler; Eugenia Haralambieva; Elias Campo; Davide Soldini; Luca Mazzucchelli; Vittoria Martin
Journal:  Mod Pathol       Date:  2016-04-29       Impact factor: 7.842

3.  A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration.

Authors:  Grzegorz Rymkiewicz; Beata Grygalewicz; Magdalena Chechlinska; Katarzyna Blachnio; Zbigniew Bystydzienski; Joanna Romejko-Jarosinska; Renata Woroniecka; Michalina Zajdel; Katarzyna Domanska-Czyz; David Martin-Garcia; Ferran Nadeu; Pawel Swoboda; Jolanta Rygier; Barbara Pienkowska-Grela; Jan Konrad Siwicki; Monika Prochorec-Sobieszek; Itziar Salaverria; Reiner Siebert; Jan Walewski
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

4.  MYC chromosomal aberration in differential diagnosis between Burkitt and other aggressive lymphomas.

Authors:  Gabriella Aquino; Laura Marra; Monica Cantile; Annarosaria De Chiara; Giuseppina Liguori; Maria Pia Curcio; Rocco Sabatino; Giuseppe Pannone; Antonio Pinto; Gerardo Botti; Renato Franco
Journal:  Infect Agent Cancer       Date:  2013-09-30       Impact factor: 2.965

5.  miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma.

Authors:  Michalina Zajdel; Grzegorz Rymkiewicz; Magdalena Chechlinska; Katarzyna Blachnio; Barbara Pienkowska-Grela; Beata Grygalewicz; Krzysztof Goryca; Maria Cieslikowska; Zbigniew Bystydzienski; Pawel Swoboda; Jan Walewski; Jan Konrad Siwicki
Journal:  Tumour Biol       Date:  2015-02-13

Review 6.  Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.

Authors:  Ruifang Sun; L Jeffrey Medeiros; Ken H Young
Journal:  Mod Pathol       Date:  2016-08-01       Impact factor: 7.842

Review 7.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

Review 8.  The impact of MYC rearrangements and "double hit" abnormalities in diffuse large B-cell lymphoma.

Authors:  Pei Lin; L Jeffrey Medeiros
Journal:  Curr Hematol Malig Rep       Date:  2013-09       Impact factor: 3.952

9.  In the South African setting, HIV-associated Burkitt lymphoma is associated with frequent leukaemic presentation, complex cytogenetic karyotypes, and adverse clinical outcomes.

Authors:  Jessica Opie; Katherine Antel; Ania Koller; Nicolas Novitzky
Journal:  Ann Hematol       Date:  2020-01-18       Impact factor: 3.673

10.  PAX5-KIAA1549L: a novel fusion gene in a case of pediatric B-cell precursor acute lymphoblastic leukemia.

Authors:  Stefanie Anderl; Margit König; Andishe Attarbaschi; Sabine Strehl
Journal:  Mol Cytogenet       Date:  2015-07-08       Impact factor: 2.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.